---
title: "Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial"
id: "nature-0-anti-lag-3-with-or-without-anti-pd-1-in-recurrent-glioblastoma-a-phase-1-trial"
canonical_url: "https://medichelpline.com/clinical-feed/nature-0-anti-lag-3-with-or-without-anti-pd-1-in-recurrent-glioblastoma-a-phase-1-trial"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04475-7"
published_at: "2026-07-10T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-0-anti-lag-3-with-or-without-anti-pd-1-in-recurrent-glioblastoma-a-phase-1-trial
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04475-7)
- **Published At:** 2026-07-10T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint implicated in T cell exhaustion and a potential therapeutic target in glioblastoma (GBM). We conducted a multicenter, open-label, phase 1 study with sequential allocation to evaluate the safety and preliminary activity of the anti-LAG-3 antibody relatlimab, administered alone or with the anti-programmed cell death protein 1 (PD-1) antibody nivolumab, in patients with recurrent GBM. Forty-six patients were treated (23 per cohort). The primary endpoint of safety was met, with maximum tolerated doses of 800 mg relatlimab for monotherapy and 160 mg relatlimab/240 mg nivolumab for combination therapy. Treatment-related grade 3–4 adverse events occurred in 6 of 23 patients receiving combination therapy and were not observed with monotherapy. Neoadjuvant administration was associated with increased intratumoral CD8 + T cell infiltration for both monotherapy and combination therapy. Exploratory analyses suggested that tumors with elevated baseline interferon signaling and increased T cell clonality were enriched among patients with durable responses to combination therapy.
## Clinical Analysis & Structured Key Points
Nature Medicine published a clinical update in Research Highlights on 10 Jul 2026. The item focuses on Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial. Review the original article for the full source wording and details.
## Related Clinical Research

- [Avoiding Cardiac Toxicity with Immune Checkpoint Inhibitors: Safety Review (Title Only Available)](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-avoidance-of-cardiac-toxicity-during-the-application-of-immune-checkpoint.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Source page lacked article content for immune checkpoint inhibitor strategies in lung cancer](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-immune-checkpoint-inhibitor-based-combinatory-and-alternative-strategies-for.md)
- [Cost-effectiveness of pembrolizumab (neoadjuvant + adjuvant) for resectable LA HNSCC in Switzerland](https://medichelpline.com/clinical-feed/pubmed-42565346.md) (DOI: 10.1080/13696998.2026.2712763)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.